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With the advent of antiretroviral therapy (ART), HIV-infected individuals are now living longer and healthier lives. However, ART
does not completely restore health and treated individuals are experiencing increased rates of noncommunicable diseases such as
dyslipidemia, insulin resistance, type 2 diabetes, cardiovascular disease, and nonalcoholic fatty liver disease. While it is well known
that persistent immune activation and inﬂammation contribute to the development of these comorbid diseases, the mechanisms
underlying this chronic activation remain incompletely understood. In this review, we will discuss emerging evidence that
suggests that alterations in cellular metabolismmay play a central role in driving this immune dysfunction in HIV patients on ART.
1. Introduction
HIV infection is now considered a chronic disease requiring
lifelong treatment with combination ART. Infected individ-
uals are living longer, healthier lives with near normal life
expectancies [1, 2]. However, ART does not completely
restore health and treated individuals are experiencing
increased rates of non-AIDS-associated comorbidities such
as cardiovascular disease (CVD), type 2 diabetes, neurocog-
nitive impairment, and cancer [3–5]. These comorbid dis-
eases represent a signiﬁcant problem for the long-term
management of HIV patients, particularly as recent studies
suggest that screening algorithms and treatments may not
be as eﬀective in infected populations [6–9]. By 2020, it is
expected that >30 million people living with HIV will have
access to ART [10]. Progress towards improving outcomes
for these individuals will depend on the identiﬁcation of
novel strategies for the prevention and treatment of these
non-AIDS- associated comorbities.
Chronic immune activation and inﬂammation persist in
HIV patients on ART [11–14]. This immune dysfunction is
associated with hypercoagulation, tissue ﬁbrosis/damage,
and organ system dysfunction, which over time contribute
to the development of non-AIDS-associated comorbidities
[15–17]. The drivers of this activation remain incompletely
understood but are thought to include ongoing HIV replica-
tion [18, 19], secondary coinfections [20, 21], and HIV-
mediated breakdown of the intestinal mucosa and subse-
quent exposure to gut microbial products [22]. However,
strategies targeting these root drivers of inﬂammation such
as ART intensiﬁcation [23–25], treatment of coinfections
[26, 27], and agents that promote mucosal repair in the
gut-associated lymphoid tissue (GALT) [28, 29] are unable
to completely resolve this persistent immune activation and
inﬂammation.
Although new antiretroviral (ARV) drugs are less toxic
and are associated with fewer metabolic complications, met-
abolic abnormalities persist in HIV patients on ART
(reviewed in [30]). Factors driving these abnormalities
include not only the eﬀects of the drugs themselves but also
the eﬀects of chronic inﬂammation, the irreversible damage
of metabolic tissues sustained prior to the introduction of
ART, host genetic risk, side eﬀects associated with other med-
ications, age-related factors, obesity and lifestyle/behaviour
(diet, exercise, and smoking) [31, 32]. Emerging evidence sug-
gests that these metabolic abnormalities may further aﬀect
immune function and contribute to the development of
non-AIDS-associated comorbidities [33, 34]. Consistent with
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these ﬁndings, immunometabolic signatures that combine
markers of immune activation/inﬂammation and metabolite
proﬁles have been shown to be strong predictors of frailty
[35], hepatic dysfunction [36], neurocognitive impairment
[37], and depression [38] in HIV patients on ART. However,
the molecular mechanisms underlying these relationships
remain incompletely characterized.
Immune responses are highly dependent on the meta-
bolic microenvironment, which alters the cell’s metabolic
status and induces eﬀector function. This metabolic repro-
gramming is required to meet the bioenergetic and biosyn-
thetic demands of the cell and to activate and regulate
gene expression, signal transduction, and epigenetic proﬁles
[39, 40]. By altering cellular metabolism, it may be possible to
shape and ﬁne tune innate and adaptive immune responses
[39]. Conversely, disruption of these interactions has been
shown to underlie the development of many noncommunic-
able diseases such as CVD and type 2 diabetes [40]. In this
review, we will discuss the range of metabolic abnormalities
observed in HIV patients on ART and explore emerging evi-
dence that suggests that these metabolic abnormalities may
play a critical role in both supporting and driving chronic
immune activation and inﬂammation in HIV infection.
1.1. Spectrum of Metabolic Abnormalities in HIV Patients on
ART. Despite the successes of ART in reducing AIDS-
associated morbidity and mortality, HIV-infected patient
populations are experiencing decreased metabolic control
and increased rates of metabolic diseases [30, 31]. Many of
these diseases are associated with dysregulated lipid and glu-
cose metabolism including dyslipidemia, insulin resistance
and type 2 diabetes, CVD, and nonalcoholic fatty liver dis-
ease (NAFLD).
1.1.1. Dyslipidemia. Dyslipidemia and altered fat distribution
(loss of subcutaneous fat and a relative increase in central fat)
are commonly observed in HIV patients on ART [41, 42].
The prevalence of these disturbances varies widely and
depends on the cohort, the fat type, and the anatomic loca-
tion of the adipose tissue [42, 43]. The type and duration of
ART have also been shown to diﬀerentially alter lipid metab-
olism. The most pronounced eﬀects are commonly observed
with protease inhibitors (PI), which increase central obesity
and lipoatrophy as well as alter circulating triglycerides,
low-density lipoprotein cholesterol (LDL-C), and high-
density lipoprotein cholesterol (HDL-C) levels [44, 45].
These alterations are associated with the inhibition of lipo-
genesis, adipocyte diﬀerentiation, a decrease in hepatocyte
clearance of chylomicron and very low-density lipoproteins
(VLDL), and the stimulation of hepatic triglyceride synthesis
[45]. Certain nucleoside reverse transcriptase inhibitors
(NRTI) and non-NRTIs (NNRTI) also alter adipogenesis
and adipocyte diﬀerentiation [43]. Some NRTIs are also
associated with mitochondrial dysfunction, which has been
shown to induce adipocyte cell death and contribute to lipo-
dystrophy [46–49]. In addition to the eﬀects of ART, persis-
tent inﬂammation in treated HIV patients has also been
shown to modify lipid proﬁles by altering lipid processing
and transport and enhancing oxidative and enzymatic
modiﬁcations of lipid molecules (reviewed in [42]). Impor-
tantly, lipids are potent immunomodulatory molecules that
can exert inﬂammatory or anti-inﬂammatory eﬀects locally
and systemically [50]. In HIV patients on ART, alterations
in lipid proﬁles may feed forward and drive further immune
activation and inﬂammation [51].
1.1.2. Insulin Resistance and Type 2 Diabetes. Insulin resis-
tance and type 2 diabetes are also common in HIV-infected
patients receiving ART [52, 53]. In the Multicenter AIDS
Cohort Study, the incidence of type 2 diabetes was found to
be more than four times greater in HIV-infected men receiv-
ing HAART than in HIV-seronegative control participants
[52]. Complex interrelationships between genetic predisposi-
tion, disease-related body changes, and metabolic eﬀects of
ART drugs have been shown to contribute to altered glucose
homeostasis [54]. Protease inhibitors have been shown to
directly target glucose transporter 4 (GLUT4) expression, a
glucose transporter expressed by adipocytes and skeletal
muscle cells. This decreased expression was found to impair
insulin-mediated uptake of glucose into adipocytes [54–56].
PI-induced alterations in glucose transport and/or metabo-
lism have also been shown to contribute to impaired insulin
secretion from β-cells [57] and altered glycogen synthesis
by hepatocytes [58], which may increase the risk of develop-
ing type 2 diabetes [59]. On the other hand, NRTIs have been
shown to aﬀect glucose metabolism and insulin resistance by
inducing mitochondrial dysfunction [60–62]. Insulin resis-
tance may also develop through indirect eﬀects of regional
body adipose tissue changes, inﬂammation, adipokine pro-
duction, and free fatty acid dysregulation on glucose homeo-
stasis [63–66]. Importantly, increased levels of circulating
glucose may support chronic immune activation and inﬂam-
mation in HIV patients on ART [67].
1.1.3. Cardiovascular Disease. CVD is now the leading cause
of morbidity in ART-treated patients and accounts for >10%
of premature deaths [2]. It has been reported that HIV-
infected individuals on ART have a twofold higher risk of
CVD compared to matched uninfected individuals [68] and
that 41.3% of ART-treated patients are at high risk for
CVD [69]. Even those with low Framingham risk scores
and no symptoms of CVD have a higher incidence of coro-
nary atherosclerosis [70–72] and an increased prevalence of
inﬂamed and noncalciﬁed atherosclerotic plaques that are
vulnerable to rupture [70, 73]. This increase in atherosclero-
sis is associated with a twofold higher risk of myocardial
infarction and fourfold higher risk of sudden cardiac death
[74, 75]. Large observational studies have shown that certain
ART drugs/regimens are associated with an increased CVD
risk [76–78], which is thought to be associated with their
metabolic side eﬀects such as dyslipidemia [77], glucose intol-
erance [52], and lipodystrophy [79, 80]. Inﬂammation is also
a key factor driving the development of HIV-associated CVD.
Inﬂammatory markers, including high-sensitivity C-reactive
protein (hsCRP), interleukin 6 (IL-6), and D-dimer, are
strong predictors of cardiac disease and mortality in HIV-
infected patients with known CVD [72, 81, 82]. Recent stud-
ies also suggest that markers of monocyte activation (soluble
2 Mediators of Inﬂammation
and cell associated) may represent powerful predictors of
early or subclinical CVD [73, 83]. Soluble CD163 (sCD163)
and soluble CD14 (sCD14) levels were found to be positively
associated with the formation of noncalciﬁed or vulnerable
plaques [83] and with arterial inﬂammation as assessed by
ﬂuorine-2-deoxy-D-glucose positron emission tomography
(18FDG-PET) in HIV patients on ART [73]. Interestingly,
a recent study also found that increased expression of
GLUT1 on monocytes is associated with markers of CVD
risk in HIV-infected individuals suggesting that increased
glucose uptake may be a more speciﬁc marker of monocyte
activation [84]. Additional studies are required to systemati-
cally examine relationships between altered metabolic abnor-
malities and persistent inﬂammation in HIV patients on
ART with CVD.
1.1.4. Nonalcoholic Fatty Liver Disease. Liver-related diseases
are becoming increasingly prominent in HIV-infected
patients [85, 86]. Coinfection with Hepatitis B virus (HBV)
and Hepatitis C virus (HCV) signiﬁcantly contribute to this
burden and increase the risk for liver-related mortality [87,
88]. However, even in the absence of HBV and HCV, mono-
infected individuals have been shown to experience increased
rates of liver disease including NAFLD [89–91]. This increase
in NAFLD is traditionally thought to be associated with
ART-related hepatotoxicity as well as ART-related lipody-
strophy, dyslipidemia, and insulin resistance [85]. However,
emerging studies suggest that ongoing inﬂammation and
persistent expression of viral proteins may also contribute
to the complex etiology of this condition [92–94]. For exam-
ple, Vpr has been shown to accelerate fatty acid ﬂux to the
liver, increase hepatic DNL, diminish hepatic fatty acid oxi-
dation, and blunt hepatic VLDL-TG export via activation
and signaling through GR, LXR-α, and PPARα/γ [95].
Importantly, the liver is one of the primary sites of energy
storage and is a central organ in glucose and lipid metabo-
lism. Alterations in liver function may have signiﬁcant eﬀects
on systemic metabolism.
1.2. Amplifying Eﬀects of Obesity and Aging in HIV Patients
on ART
1.2.1. Role of Obesity. The prevalence of obesity is increasing
among HIV-infected persons. In some cohorts, greater than
50% of infected individuals are classiﬁed as overweight or
obese [96, 97]. Obesity in HIV-infected populations leads to
the onset of further metabolic abnormalities and increased
risk for type 2 diabetes, atherosclerosis, dyslipidemia, hyper-
tension, and malignancies [96]. While the etiology of this
morbidity is likely multifactorial, the synergistic eﬀects of
obesity on persistent systemic inﬂammation observed in
HIV patients on ART may play a role in amplifying this risk
[98, 99]. Interestingly, a recent study in mice found that ART
treatment on a high-fat diet was associated with increased fat
mass accumulation, impaired glucose tolerance, and potenti-
ated insulin resistance compared to those on low-fat diet,
suggesting that high-fat diets may further amplify the meta-
bolic eﬀects of ART [100]. This cumulative metabolic dys-
function was associated with augmented proinﬂammatory
signaling within adipose tissue consistent with macrophage
inﬁltration [100]. These ﬁndings need to be validated in
HIV patients on ART.
1.2.2. Role of Aging. By 2030, it is estimated that three out of
every four HIV patients will be over the age of 50, more
than 80% will have at least one age-related disease and
approximately one-third will have at least three age-related
diseases [101]. In uninfected populations, aging is associ-
ated with alterations in body composition [102, 103], a
decrease in the resting metabolic rate (RMR) and variability
in oxygen consumption and free radical production leading
to increased oxidative stress [104–108]. Further, aging is asso-
ciated with dysregulation of the immune system via immune
exhaustion (immunosenescence) and chronic inﬂammation
(inﬂammaging) [109, 110]. The impact of aging on metabolic
and inﬂammatory dysregulation in ART-treated patients is
not fully understood but it is expected to further increase
the rates of non-AIDS-associated comorbidities in these pop-
ulations. Interestingly, it has been hypothesized that age-
associated alterations in cellular metabolism and reduced
clearance of metabolic waste may represent a major source
of inﬂammatory stimuli driving age-associated chronic
inﬂammation, termed inﬂammaging [111]. While further
studies are required to conﬁrm these ﬁndings, preliminary
studies may support this hypothesis in HIV patients on
ART [37].
1.3. Alterations in the Metabolic Microenvironment in HIV
Patients on ART. To date, metabolic abnormalities in HIV
patients on ART have been primarily described using estab-
lished clinical markers of metabolic function such as total
cholesterol, HDL-C, LDL-C, triglycerides, HOMA-IR, and
panels to assess kidney and liver function. However, these
biomarkers represent only a subset of the total metabolic pro-
cesses that may be altered in HIV infection. Systems-based
approaches such as metabolomics have started to provide
critical new insights into the spectrum of metabolic abnor-
malities observed in HIV patients on ART.
1.3.1. Altered Plasma/Serum Metabolome in HIV Patients on
ART. Plasma/serum is the primary carrier of >4000 small
molecules in the body and plays a critical role in transporting
nutrients and metabolic waste to the various organ systems
[112]. Using metabolomic approaches to characterize abnor-
malities, a recent study found that good immunological
response (>250 CD4+ cells/μl after 36 months on ART) was
associated with increased HDL, total cholesterol, branched
chain amino acids, and tyrosine levels where as poor immu-
nological response was associated with increased levels of
glycolytic metabolites, LDL, and VLDL [113]. Another study
identiﬁed ﬁve diﬀerent metabolite ratios capable of accu-
rately identifying rapid progressors or immunological nonre-
sponders on ART at baseline. These ratios used metabolites
associated with acylcarnitine hydroxylation and carboxyla-
tion as well as the catabolism of branched chain amino acids,
lysine, organic acids, and tryptophan [114]. Untargeted
approaches have also identiﬁed unique signatures associated
with PI vs. NNRTI-based treatment regimens. Consistent
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with previous studies, PI treatment was shown to have sig-
niﬁcant eﬀects on the plasma lipid proﬁles including altered
bile acids, sulfated steroid, polyunsaturated fatty acid, and
eicosanoid metabolism [36]. These alterations had substan-
tial overlap with those reported in NAFLD and were found
to correlate with markers of inﬂammation, microbial trans-
location, and hepatic function [36]. Alternatively, nuclear
magnetic resonance (NMR) spectroscopy analysis found
that VLDL metabolism, total triglyceride levels, and lactate
levels were independently associated with the use of
NNRTI-based ART [113]. The authors also suggested that
these metabolite proﬁles were better predictors of HIV/
ART-related dyslipidemia and atherogenic risk than con-
ventional lipid measurements. Interestingly, several metabo-
lomic studies have identiﬁed mitochondrial metabolism as
an important player in the development of non-AIDS-
associated comorbidities. Bailin et al. [115] found that insu-
lin resistance in HIV patients on ART is associated with
lower plasma levels of acylcarnitines and decreased acylcar-
nitine : FFA ratios suggesting that impaired fatty acid uptake
and/or mitochondrial oxidation is a central aspect of glucose
intolerance in this population. Alternatively, Okeke et al.
[116] suggested that short-chain dicarboxylacyl carnitines
as well as glutamine and valine metabolites may represent
valuable markers of CVD risk in HIV patients on ART.
The potential mechanisms driving mitochondrial dysfunc-
tion are described below.
1.3.2. Metabolite Proﬁles in Other Biological Fluids from HIV
Patients on ART. In addition to the alterations in plasma/
serummetabolome, studies have identiﬁed altered metabolite
proﬁles in a variety of other biological ﬂuids. In cerebrospinal
ﬂuid, alterations in aspartate and glutamine metabolism,
phenylalanine and tyrosine metabolism, carnitine metabo-
lism, and energy metabolites were found to be correlated with
neurocognitive impairment and increased inﬂammation in
HIV-infected individuals on ART [37]. These alterations
overlapped with metabolic alterations seen in HIV-negative
older individuals suggesting accelerated aging in patients tak-
ingART [37]. Similarly, Dickens et al. [117] found that defects
in executive function, recall, and motor function were associ-
atedwith increased levels of energymetabolites, such as lactate
and citrate in the CSF from HIV patients on ART. These
metaboliteswere found to diﬀerentiate groupswithworsening
neurocognitive function from individuals with improving
neurocognitive function [117]. In oral wash samples, HIV-
infected patients had elevated levels of p-cresol sulfate, nucle-
otides, phenylalanine, and tryptophan and decreased levels of
fucose, fumarate, and N-acetylglucosamine [118]. Interest-
ingly, a recent study found that metabolite diﬀerences in
bronchoalveolar lavage ﬂuid from HIV patients in ART were
predominantly in bacterial products likely reﬂecting alter-
ations in the lung microbiome [119]. Further studies are
required to better characterize other interactions between
these altered tissue microenvironments and immune dys-
function in HIV patients on ART.
1.4. Cellular Metabolic Reprogramming in HIV Patients
on ART. In addition to alterations in the metabolic
microenvironment, recent studies suggest that immune cells
undergo dysregulated metabolic reprogramming in viral
infections. Innate and adaptive immune function is inti-
mately linked to metabolism. This reprogramming not only
supports increased bioenergetic and anabolic demands but
also drives speciﬁc eﬀector functions [39, 40]. In antiviral
immune responses, type I IFNs regulate protein synthesis,
proliferation, membrane composition, and the nutritional
microenvironment to prevent viral entry and inhibit viral
replication [120–122]. A detailed review of IFN-mediated
reprogramming is beyond the scope of this review and can
be found elsewhere [123]. On the other hand, viruses are
obligate parasites that are completely reliant on host cell
metabolism. They manipulate cellular metabolism including
glycolysis, fatty acid synthesis, and glutaminolysis to create
an intracellular metabolic niche, which supports virion pro-
duction and promotes survival of infected cells. This intracel-
lular niche is highly speciﬁc and dependent on the virus. For
example, Dengue and Zika infections increase glycolytic ﬂux
and mitochondrial ATP production to support infection
[124, 125]. Alternatively, HBV and HCV depend on aerobic
glycolysis to support ATP production and reprogram mito-
chondrial function for ROS production [126, 127]. At the
level of lipid metabolism, Dengue and Vaccinia viruses use
newly generated fatty acids as a means of producing ATP
via fatty acid oxidation (FAO) [128, 129]. However, others
hijack cholesterol metabolism and redistribute newly synthe-
sized cholesterol to generate virion membranes [130, 131].
Given the critical role of cellular metabolism in supporting
viral infections, an in-depth understanding of HIV-
associated metabolic reprogramming may identify novel bio-
markers and therapeutic targets to treat infection.
1.4.1. Increased Cellular Bioenergetics in HIV Infection. The
ﬁeld is just beginning to understand the implications of met-
abolic reprogramming on HIV infection. Among the best
characterized alterations are related to glucose metabolism.
Glucose is a central source of energy and biosynthetic precur-
sors that feed into glycolysis, pentose phosphate pathway
(PPP), tricarboxylic acid (TCA) cycle, and oxidative phos-
phorylation (OXPHOS) [132, 133]. During HIV infection,
glucose metabolism is elevated at the level of glucose trans-
port and pathway ﬂux [67, 134–136]. Recent studies have
reported increased Glut1 expression on both monocytes
and CD4+ T cells during HIV infection [67, 84, 137]. This
upregulation on CD4+ T cells is associated with increased T
cell activation (CD38, HLA-DR) and is inversely correlated
with absolute CD4 count irrespective of treatment status
[137]. Interestingly, this upregulation persists in immunolog-
ical nonresponders on long-term ART even when other
markers of activation have returned to almost normal levels.
Consistent with these ﬁndings, Masson et al. [138] identiﬁed
a polymorphism within the GLUT1 gene SLC2A1, which ele-
vates GLUT1 expression on CD4 T cells, that was linked to
poor CD4 T cell recovery and HIV disease progression in
untreated and treated individuals. On monocytes, the highest
levels of Glut1 expression and glucose uptake are found on
proinﬂammatory monocyte subsets [84]. This elevated
glucose transport is associated with increased levels of
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inﬂammatory cytokine production (TNF-α and IL-6) [34]
and has been linked to subclinical cardiovascular disease
[84] and frailty in HIV patients on ART [35]. Given these
ﬁndings, there is an increasing interest in GLUT1 as a pos-
sible target for limiting inﬂammation and the development
of comorbidities in HIV patients on ART. In addition to
glucose, other carbohydrates, fatty acids, and amino acids
serve as alternative energy sources to support ATP produc-
tion. Hegedus et al. [134] found that CD4+ T cells cultured
in galactose had increased survival rates and supported
lower levels of HIV replication compared to culturing under
standard conditions. Studies also suggest that alternative
energy sources, such as galactose, can amplify antiviral
immunity [139]. These ﬁndings may open new avenues of
investigation.
1.4.2. Altered Lipid Biosynthesis in HIV Infection. Lipids are a
central component of the plasma membrane and other cellu-
lar compartments including the nuclear membrane, the
endoplasmic reticulum, the Golgi apparatus, and traﬃcking
vesicles such as endosomes and lysosomes. They also serve
as a source of energy and facilitate signaling for a wide range
of cellular processes [140, 141]. HIV has been shown to pro-
mote fatty acid and cholesterol biosynthesis to support viral
replication, which requires a signiﬁcant supply of free FAs,
LDL, and apolipoprotein A1 [142, 143]. Recent studies sug-
gest that Nef plays a central role in this reprogramming
[144–147]. Transcriptional proﬁling of CD4+ T cells infected
with wild-type vs. Nef-deleted HIV found dysregulated
expression of genes associated with lipid synthesis and fatty
acid oxidation, which correlated with decreased cellular lipid
content [146]. This may be due to Nef-mediated suppression
of PPARγ expression, which transcriptionally regulates lipid
metabolism, glucose homeostasis, and cellular diﬀerentiation
[147]. Alternatively, Nef transfected into cell lines has been
shown to increase cholesterol synthesis and transport of cho-
lesterol to lipid rafts to facilitate viral entry and assembly
[144]. Interestingly, monocytes actively increase cholesterol
eﬄux in early stages of HIV infection. However, over time,
this eﬄux decreases and cholesterol accumulates causing
the formation of foam cells [148]. Further characterization
of lipid reprogramming in both HIV-infected and HIV-
uninfected bystander cells may identify novel mechanisms
driving HIV pathogenesis.
1.4.3. Altered Amino Acid Metabolism in HIV Infection. Dys-
regulated amino acid metabolism is also a central feature of
metabolic reprogramming in HIV infections. Alterations in
tryptophan (Trp) metabolism are among the best character-
ized given the immunomodulatory role of Trp and its catab-
olites [149, 150]. Trp is an essential amino acid that can be
metabolized by tetrahydrobiopterin-dependent tryptophan-
hydroxylase to produce serotonin or catabolized by TRP
2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase
(IDO-1) to produce kynurenine and its derivatives. This
catabolic breakdown via the kynurenine pathway also con-
tributes to the biosynthesis of nicotinamide adenosine
dinucleotides (NAD/NADH). During HIV infection, IFN
responses and TLR engagement induce intracellular IDO
expression in macrophages and dendritic cells, which
increase circulating levels of immunomodulatory trypto-
phan catabolites such as kynurenine and quinolinic acid
[151]. This increase in catabolites is associated with higher
levels of immune activation and inﬂammatory cytokine
production and has been shown to correlate with the degree
of microbial translocation [151, 152]. Increased IDO-1
activity has also been shown to skew CD4+ T cell diﬀerentia-
tion into regulatory T cells (Tregs) instead of T helper (Th17)
cells and directly impair T cell responses [151, 152]. Further,
IDO inhibitor 1-methyl-tryptophan (1-MT) has been shown
to restore CD4 and CD8 T cell proliferation and T cell activa-
tion to normal levels during HIV infection in vitro [153, 154].
In SIV models, 1-MT was shown to lower plasma and lymph
node viral loads and increase levels of serum tryptophan
[155]. Altered tryptophan metabolism has also been linked
to the development of neurological disorders in HIV patients
on ART. Increased ﬂux down the kynurenine pathway not
only limits serotonin production but is also associated with
increased levels of kynurenine metabolites that have neuro-
toxic properties [156]. Preliminary studies have started to
examine the role of other amino acid pathways in HIV infec-
tion. In particular, diminished breakdown of phenylalanine
(Phe) to tyrosine (Tyr) has been shown to correlate with
the expression of neopterin, as well as with HIV-RNA levels
and CD4 counts in HIV-infected individuals [156, 157].
This decrease may be linked to reduced phenylalanine
4-hydroxylase (PAH) activity due to a loss of neopterin,
a precursor of PAH’s cofactor tetrahydrobiopterin [157].
Importantly, PAH and tetrahydrobiopterin play a critical
role in catecholamine synthesis such a dopamine. Decreased
availability of dopamine in the central nervous system has
been shown to correlate with decreased neuropsychological
functions, which cannot be fully rescued by ART [158].
1.5. Targeting mTOR and AMPK to Treat HIV Infection.
Mechanistic targets of rapamycin (mTOR) and AMP-
activated protein kinase (AMPK) are master regulators of
metabolic gene expression, which aﬀect cellular metabolism
during viral infections [159, 160]. Emerging evidence sug-
gests that both mTOR and AMPK may play a central role
in HIV pathogenesis and may represent new targets to regu-
late viral replication. The mTOR complex is composed of two
distinct complexes, mTORC1 and mTORC2, with distinct
signaling activities. mTORC1 functions as a nutrient sensor,
capable of controlling protein synthesis while mTORC2 reg-
ulates cytoskeleton organization, metabolism, and cell sur-
vival [161]. Recent studies have shown that HIV induces
mTOR phosphorylation and activation and that rapamycin,
a potent and speciﬁc inhibitor of mTORC1, inhibits virus
replication both in vitro and in vivo [162–164]. The mecha-
nisms underlying mTOR-mediated inhibition of viral repli-
cation are likely multifactorial including direct eﬀects on
Tat-dependent and Tat-independent transactivation of HIV
promoter [165] as well as Gag- and Vif-mediated comman-
deering of mTOR-associated lysosome positioning and traf-
ﬁcking, which mediate virus traﬃcking, assembly, and/or
budding [166]. mTOR inhibition may also limit viral replica-
tion by correcting immune dysfunction commonly observed
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in HIV patients such as enhanced antiviral responses and
increased memory CD8+ T cell formation, reduced inﬂam-
matory cytokine production, and reversal of PD-1-mediated
T cell exhaustion [164, 167–169]. The role of AMPK in
HIV infection is less clearly deﬁned. AMPK is a central regu-
lator of energy expenditure and fatty acid biosynthesis, which
has been shown to modulate EF2 and TSC2/mTOR pathways
including NF-κB activation [170]. This regulation of energy
expenditure is mediated by NAD+ metabolism and SIRT1
activity [171]. In HIV-infected HeLa cells, activation of
AMPK and SIRT1 has been shown to inhibit Tat-induced
HIV LTR transcription and replication [172]. Conversely,
Tat-induced reductions in NAD+ levels and SIRT1 activity
have been shown to diminish AMPK activity [172]. Consis-
tent with these ﬁndings, restoration of NAD+ levels by tan-
shinone II-induced nicotinamide phosphoribosyltransferase
(Nampt) expression and increased AMPK activation resulted
in reduced Tat-mediated HIV transactivation and reduced
reactive oxygen species production [173]. Alternatively,
AMPK activators such as metformin or AICAR are currently
being tested with clinical trials to reactive latent HIV infec-
tion. However, emerging evidence suggests that AMPK is
not directly involved in viral reactivation but may instead
coordinate the process via PKC [174]. Based on these
observations, more research is required to better under-
stand the complexities surrounding AMPK’s role during
HIV infection.
1.6. Central Role of Mitochondrial Reprogramming in Driving
Chronic Inﬂammation and Immune Dysfunction in HIV
Patients on ART. Mitochondria are highly dynamic organ-
elles that regulate a variety of cellular functions including
cellular respiration and energy production, cellular metabo-
lism, cell signaling, cell death and proliferation, Ca2+ homeo-
stasis, ROS production and redox status [175]. To ensure
appropriate and timely function, mitochondrial structure
and morphology is tightly regulated by the processes of mito-
chondrial ﬁssion, fusion, and mitophagy [175]. Dysregula-
tion of these processes leads to altered cellular metabolism,
increased ROS, and increased inﬂammatory responses and
cellular senescence, which have important roles in driving
metabolic and neurological diseases [176]. In the context of
HIV patients on ART, mitochondrial dysfunction is driven
by both the virus and ART. While it is clear that mitochon-
drial dysfunction contributes to the development of non-
AIDS-associated comorbidities in HIV patients on ART,
the underlying mechanisms remain poorly characterized.
1.6.1. HIV-Associated Reprogramming of Mitochondrial
Function. As with other viruses [177], HIV has been shown
to contribute to mitochondrial dysfunction and apoptosis
in CD4 and CD8 T cells [178, 179]. The mechanisms under-
lying this dysfunction include depletion of mitochondrial
DNA (mtDNA), decreased mitochondrial gene expression,
reprogramming of energy production via oxidative phos-
phorylation, and increased ROS production [180–182]. A
number of viral proteins have been shown to interact with
mitochondria. Tat has been shown to reduce mitochondrial
membrane potential in the mouse liver, heart, and brain
tissues [183] and induce ROS production [184] and dysregu-
late calcium homeostasis in neurons [185]. Further, the expo-
sure of neurons to Tat leads to decreased mitochondrial
diameter and perimeter as well as fragmentation and redistri-
bution of mitochondria within the neurons, which leads to
loss of mitochondrial transportation [186]. Alternatively,
Vpr has been shown to reduce mitochondrial membrane
potential (MMP) leading to mitochondrial swelling and apo-
ptosis [187]. In neurons, Vpr has also been shown to aﬀect
axonal mitochondrial transport and ATP production, which
may contribute to the development of HIV-associated neuro-
cognitive disorder (HAND) [188]. Similarly, envelope glyco-
protein 120 (gp120) induces dysregulation of calcium
homeostasis, increases oxidative stress, and drives apoptosis
in neurons [185, 189]. Further, gp120 has been shown to
increase mitochondrial fusion/mitochondrial size [190] and
increase extracellular acidiﬁcation rate (ECAR), which corre-
lates with neuroinﬂammation and neurodegeneration pri-
mary mouse neurons in vitro [191]. Collectively, these
ﬁndings suggest that HIV and associated protein may have
diﬀerential eﬀects on speciﬁc cell populations.
1.6.2. ART-Induced Alterations in Mitochondrial Function
and Metabolism. ARV drugs are also an important driver
of mitochondrial dysfunction in HIV patient on ART
[192]. While ﬁrst-generation ARV drugs were associated
with signiﬁcant side eﬀects in metabolically active tissues
including adipose tissue, muscle tissue, and hepatic tis-
sue, next-generation options have fewer serious adverse
eﬀects [30, 192]. Toxicity proﬁles of individual drugs
have been examined in terms of absolute risk of meta-
bolic complications; however, the molecular mechanisms
underlying this reprogramming and the functional conse-
quences may vary by cell type and across diﬀerent tissue
microenvironments.
NRTIs are commonly used antiretroviral drugs that rep-
resent the backbone of most ﬁrst-line treatment regimens.
Early studies identiﬁed pronounced mitochondrial dysfunc-
tion using NRTI given their interactions with DNA Pol-γ,
the only known DNA polymerase in the human mitochon-
dria [193]. Some NRTIs can act as substrates for Pol-γ and
interfere with mtDNA synthesis, reducing mtDNA content,
ETC activity, and oxidative phosphorylation and increasing
mitochondrial ROS production [60, 192]. However, a num-
ber of recent studies have also reported dysfunction in the
absence of mtDNA depletion suggesting secondary eﬀects
of NRTI on mitochondrial function [194]. These alterations
include altered nucleotide phosphorylation and direct mito-
toxic eﬀects on mitochondrial respiration and ATP produc-
tion [80, 195, 196]. In particular, AZT has been shown to
inhibit the mitochondrial adenylate kinase and adenosine
nucleotide translocator in isolated mitochondria [46] and
promote mitochondrial ROS production by directly inhibit-
ing the electron transport chain [196, 197]. Other NRTIs have
been shown to aﬀect complex IV activity and inhibit complex
I function [60, 196, 198]. Importantly, these toxicities can be
diﬃcult to reverse and can be life-threatening and careful
evaluation of the mechanisms underlying this mitochondrial
dysfunction will be critical in reducing this toxicity.
6 Mediators of Inﬂammation
NNRTIs do not inhibit Pol-γ or reduce mtDNA, but have
been shown to alter mitochondrial function [192]. In partic-
ular, efavirenz (EFV) has been shown to increase mitochon-
drial mass, decrease mitochondrial membrane potential,
increase ROS production, and induce apoptosis via intrinsic
pathway (cytochrome c release and caspase 9 activity) in
hepatic cell lines [199]. Blas-García et al. [195] also found
that EFV inhibits complex I leading to increased ROS pro-
duction and decrease ATP production, which drive drug-
associated hepatotoxicity. In neuronal cell lines and primary
neurons, EFV was shown to cause mitophagy, alter mito-
chondrial morphology, increase mitochondrial depolariza-
tion, and decrease ATP production [200]. In mouse
neurons, EFV and nevarapine (NVP) inhibit complex IV of
the ETC [201]. Interestingly, Weib et al. found that these
eﬀects were worsened by coadministration of the protease
inhibitor (PI) and nelﬁnavir (NFV).
Mitochondrial dysfunction has also been reported fol-
lowing PI treatment. In human preadipocytes, mitochondrial
membrane potential was signiﬁcantly decreased by saquina-
vir (SQV) [202]. In neuroblastoma cell lines, ritonavir
(RTV) was associated with mitochondrial damage, ROS pro-
duction, and apoptosis [203]. In PBMCs, however, there have
been contradictory results with increased MMP and cell sur-
vival, suggesting that these eﬀects may be dependent on the
cell type and the state of cellular activation [204].
1.6.3. Potential Consequences of Mitochondrial Dysfunction
in HIV Patients on ART. Mitochondrial structure and func-
tion play a critical role in regulating immune cell function
[205, 206]. In particular, mitochondria have been shown
to act as a scaﬀold to facilitate the activation of immune
signaling pathways including antiviral immune responses.
They have also been shown to produce chemical messen-
gers (ROS, bioactive metabolites) that activate a variety of
immune functions and pathways [207–209]. In particular,
mitochondrial-derived molecules, such as N-formyl peptides
and mtDNA, have been shown to trigger damage-associated
molecular pattern (DAMP) inﬂammatory responses [207].
Further, TCA cycle metabolites such as succinate and citrate
have been shown to activate inﬂammatory responses. Specif-
ically, succinate accumulation has been shown to stabilize
HIF-1α and upregulate proinﬂammatory cytokine produc-
tion (IL-1β) during bacterial responses [209]. Increased cit-
rate and mitochondrial citrate carrier levels also activate
inﬂammatory responses but instead through NF-κB signaling
[209]. We cannot forget that mitochondria also represent an
important source of ROS, which has been shown to activate
the NLRP3 inﬂammasome and stabilize HIF-1α expression
and activation of NF-κB [210]. Further studies are required
to evaluate if any of these mechanisms contribute to persis-
tent inﬂammation and chronic immune activation in HIV
patient on ART.
2. Conclusions
Low levels of chronic inﬂammation and immune activation
play a central role in driving the development of non-
AIDS-associated comorbidities in HIV patients on ART.
While the newest generation of antiretroviral drugs is asso-
ciated with reduce toxicity, metabolic abnormalities persist
in those on treatment [30]. Emerging evidence suggests
that these metabolic abnormalities interact with immune
cells to drive immune dysfunction and persistent inﬂam-
mation [33, 34]. Future studies should focus on unraveling
these complex interrelationships to identify new therapeutic
targets that limit inﬂammation and improve outcomes in
HIV patients on ART.
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